@entity2184 is the most common @entity5 of the adult eye. Many @entity1 will develop @entity3 , for which there is no standard of care. Therefore, we sought to review our experience with treating this @entity5 . We retrospectively reviewed all of the cases of metastatic @entity2184 seen at the Mayo Clinic, Rochester, Minnesota, USA, between 1 January 2000 and 1 August 2013. Overall survival rates were compared among @entity1 treated with local therapies (LTs), ipilumumab, bevacizumab, or kinase inhibitors. A total of 101 @entity1 were included in the study, among whom 59% were male; the median age was 62 years (interquartile range 54-71), and 92% had an Eastern Cooperative Oncology Group performance status of 0-1. Treatment with LT was associated with increased median overall survival: 26 months (n=46; interquartile range 20-44) versus 9.1 months (n=55; 4.1-20, P<0.0001). No significant survival benefit was seen with the use of bevacizumab (25 vs. 12 months; P=0.09), ipilimumab (28 vs. 13 months; P=0.07), or kinase inhibitors (24 vs. 13 months; P=0.06). Multivariate analysis showed LT as the only therapy to significantly improve survival (risk ratio 0.23, P=0.0003). However, these @entity1 had better markers of prognosis at the time of treatment. These data suggest that survival was improved in @entity1 who were amenable to LTs; however, they had better prognostic markers at diagnosis of @entity3 . Ongoing prospective clinical trials will define the roles of these novel agents in this @entity1 population.

The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic XXXX .

@entity5 :: ('MESH:D009369', 'Disease') :: ['neoplasm'] @entity2184 :: ('MESH:C536494', 'Disease') :: ['Uveal melanoma', 'uveal melanoma'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease']
@entity2184 :: (MESH:C536494,Disease) :: ['uveal melanoma']
